Second-Generation Long-Acting Injectable Antipsychotics and the Risk of Treatment Failure in a Population-Based Cohort
Introduction: Second-generation long-acting injectable antipsychotics (SG-LAIAs) may improve outcomes compared to other antipsychotics. Real-world studies using linked administrative databases play an important role in assessing the comparative effectiveness of antipsychotic medications.Methods: We...
שמור ב:
Main Authors: | Donica Janzen (Author), James M. Bolton (Author), Christine Leong (Author), I fan Kuo (Author), Silvia Alessi-Severini (Author) |
---|---|
פורמט: | ספר |
יצא לאור: |
Frontiers Media S.A.,
2022-05-01T00:00:00Z.
|
נושאים: | |
גישה מקוונת: | Connect to this object online. |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
פריטים דומים
-
Moving towards Universal Coverage of Direct-Acting Antiviral Therapies for Hepatitis C Infection in Canada: An Environmental Scan of Canadian Provinces and International Jurisdictions
מאת: Samantha Myers, et al.
יצא לאור: (2018) -
An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use
מאת: Amy M. VandenBerg, PharmD, BCPP
יצא לאור: (2022) -
Comment on "An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use"
מאת: Still Daniel PharmD, BCPP, et al.
יצא לאור: (2023) -
The place of long-acting injectable antipsychotics in the treatment of schizophrenia
מאת: John M. Kane, et al.
יצא לאור: (2023) -
Response to comment on the recently published article "An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use"
מאת: VandenBerg Amy M. PharmD, BCPP
יצא לאור: (2023)